Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent Starts US Trial of "Pivotal" CD47 Immunotherapy

publication date: Mar 22, 2019

Innovent Biologics of Suzhou has begun a US Phase I trial of its anti-CD47 mAb candidate (IBI188) in patients with advanced malignant tumors. By binding to the CD47 antigen on tumor cells, IBI188 is expected to block the CD47-SIRPα signaling pathway, inhibit the "do not eat me" signal, and promote the phagocytosis of tumor cells by macrophages. Innovent called IBI188 a "pivotal product in our pipeline of cancer immunotherapies." More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital